



Diagnosis & staging

28,229

people were diagnosed with kidney cancer in 2019 - 2021

58%

of people with kidney cancer were diagnosed at stage T1 and any N/M category

21%

of people had metastases

69

years

age at diagnosis (median)
Interquartile range 59 - 77 years

64%

of people were male

82%

of people with kidney cancer had a **multi-disciplinary team meeting recorded***



2%

of people with kidney cancer had **consented for a clinical trial**

*Data completeness measure

Treatment Allocation

20%

of people with a small renal mass had a biopsy



69%

of people with a T3+ or 10cm+ or N1 and M0 Renal Cell Carcinoma (RCC) had radical nephrectomy within 31 days of decision to treat.



Surgery

76%

of people with T1b-3NxM0 RCC underwent surgery



67%

of people with T1aN0M0 underwent nephron sparing treatment



Systemic Anti-Cancer Therapy (SACT)

48%

of people with metastatic RCC received initial SACT within 12 months of diagnosis



3%

of people with kidney cancer died within 30 days of SACT treatment



T3+ and/or 10cm+ and/or N1 and M0 RCC - Tumour extends into major veins or perinephric tissues or invades beyond Gerota fascia and/or tumour more than 10cm in size and/or metastasis in regional lymph node(s)

T1b-3NxM0 RCC - Tumour is more than 4cm in size or tumour extends into major veins or perinephric tissues with no distant metastasis

T1aN0M0 RCC - Tumour is less than or equal to 4cm in size with no regional lymph node metastasis and no distant metastasis

Diagnosis & staging

490 people were diagnosed with kidney cancer in 2022


age at diagnosis (median) Interquartile range 60 - 78 years

46% of people with kidney cancer were diagnosed at stage T1 and any N/M category

21% of people had metastases

65% of people were male


99% of people with kidney cancer had a **multi-disciplinary team meeting recorded***




*Data completeness measure

Treatment Allocation

80% of people with T2-3NxM0 Renal Cell Carcinoma (RCC) underwent surgery







Treatment	Number of people
people with T2-3NxM0 RCC underwent surgery	86
people with T2-3NxM0 RCC did not have surgery	21

Systemic Anti-Cancer Therapy (SACT)


57% of people with metastatic RCC received initial SACT within 12 months of diagnosis






SACT Receipt	Number of people
people with metastatic disease received SACT	38
people with metastatic disease did not receive SACT	29

3% of people with kidney cancer died within 30 days of SACT treatment





Mortality	Number of people
people with kidney cancer who died within 30 days of receiving SACT	2
people with kidney cancer who did not die within 30 days of receiving SACT	57

T3+ and/or 10cm+ and/or N1 and M0 RCC - Tumour extends into major veins or perinephric tissues or invades beyond Gerota fascia and/or tumour more than 10cm in size and/or metastasis in regional lymph node(s)
T2-3NxM0 RCC - Tumour is more than 7cm in size or tumour extends into major veins or perinephric tissues with no distant metastasis
T1aN0M0 RCC - Tumour is less than or equal to 4cm in size with no regional lymph node metastasis and no distant metastasis